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Abstract.	
	
There	 were	 examined	 65	 children	 with	 partially	 controlled	 and	 uncontrolled	
bronchial	asthma	 (BA)	 in	 the	exacerbation	phase	at	 the	age	of	5-7	years.	Acute	
respiratory	 viral	 infections	 were	 often	 complicated	 by	 wheezing	 (49.2%)	 and	
pneumonia	 (16.8%).	 Unfortunately,	 most	 of	 these	 episodes	 were	 treated	 using	
antibacterial	therapy	despite	normal	values	of	the	complete	blood	count	and	no	
infiltrative	 changes	 in	 the	 chest	 radiography.	 Children	 of	 Group	 I	 underwent	
basic	therapy	of	BA	in	the	form	of	inhaled	corticosteroids	(ICS),	patients	of	Group	
II	 received	antileukotriene	drug	 –	montelukast	 (Milukante)	 in	addition	 to	basic	
therapy	of	BA.	When	assessing	the	values	of	peakflowmetry	a	peak	flow	rate	was	
found	 to	 be	 improved	 in	 all	 children	 (р<0.001),	 however,	 in	 children	 who	
additionally	 received	 montelukast	 better	 parameters	 of	 the	 average	 daily	
bronchial	patency	 (ADBP)	were	observed	77.29±1.17%	vs.	72.87±0.73%	in	Group	 І	
(р<0.05).	There	was	a	similar	tendency	when	assessing	the	increase	in	the	ADBP	
19.9±1.1%	 and	 23.35±1.18%	 in	 Group	 І	 and	 ІІ,	 respectively.	 After	 inpatient	
treatment,	 patients	 were	 prescribed	 monotherapy	 with	 ICS	 (Group	 I)	 or	
montelukast	 (Group	 II)	 for	 3	 months.	 In	 children	 who	 received	 montelukast	
parameters	of	the	ADBP	were	found	to	be	higher	81.29±1.17%	vs.	89.27±1.11%	 in	
Group	 І	 (р<0.05)	 and,	 accordingly,	 the	 assessment	 of	 general	 well-being	 was	
higher,	 too.	 Such	 differences	 between	 groups	 are	 explained	 by	 the	 fact	 that	
patients	preferred	taking	montelukast	to	taking	ICS.	
 Copyright	©	Author(s),	2016	
	
	
	
	
	
	
Galician	Medical	Journal,	Vol.	23,	No.	1(2016)	
	
journal	homepage:	http://ojs.ifnmu.edu.ua/index.php/gmj/ 
8	
Problem	statement	and	analysis	of	the	recent	research	
In	recent	years	antileukotriene	drugs	have	been	widely	used	in	treatment	of	many	allergic	
diseases	in	general,	and	bronchial	asthma	(BA)	in	particular	[1,	2,	4,	9,12].	
Leukotrienes	(LT)	are	biologically	active	mediators	that	are	formed	due	to	arachidonic	acid	
metabolism	via	the	5-lipoxygenase	pathway.	They	may	be	formed	in	eosinophils,	basophils,	mast	
cells,	 alveolar	 macrophages.	 There	 are	 two	 types	 of	 LT:	 cysteinyl	 LT	 (LTC4,	 LTD4,	 LTE4)	 and	
hydroxyleukotrienes	(LTB4).	Cysteinyl	LT	play	an	important	role	in	the	pathogenesis	of	BA	causing	
bronchoconstriction,	 stimulating	 bronchial	 mucus	 secretion,	 reducing	 mucociliary	 clearance,	
increasing	 vascular	 permeability	 and	 inducing	 the	 migration	 of	 eosinophils	 and	 neutrophils	 to	
inflammatory	focus	[7].	
Antileukotriene	 drugs	 are	 divided	 into	 four	 groups:	 5-lipoxygenase	 inhibitors;	 FLAP	
inhibitors	 binding	 to	 arachidonic	 acid;	 sulphidopeptide	 (cysteinyl)	 leukotriene	 antagonists;	 LTB4	
receptor	antagonists.	The	most	studied	groups	are	5-lipoxygenase	inhibitors	and	sulphidopeptide	
leukotriene	 antagonists.	 In	 Ukraine	 drug	 of	 the	 latter	 group	 -	 montelukast	 (e.g.	 Milukante)	 is	
registered	[6,	7].	
Many	medical	guidelines	 including	the	Global	 Initiative	for	Asthma	 (GINA),	the	PRACTALL	
(Practicing	 Allergology)	 Report	 on	 Asthma	 Treatment	 in	 Children,	 British	 Guideline	 on	 the	
Management	 of	 Asthma,	 Allergic	 Rhinitis	 and	 its	 Impact	 on	 Asthma	 (ARIA)	 recommend	
antileukotriene	drugs	as	a	means	of	effective	controlling	the	course	of	the	disease	[2,	9].	
According	 to	 unified	 clinical	 protocol	 of	 primary,	 secondary	 (specialized)	 medical	 care	
“Bronchial	Asthma	in	Children”	montelukast	is	used	as	monotherapy	as	an	alternative	to	inhaled	
corticosteroids	 (ICS)	 in	 treating	mild	persistent	BA	and	virus-induced	wheezing	 in	 children	with	
intermittent	 BA.	 It	 also	 may	 be	 prescribed	 additionally	 to	 ICS	 if	 the	 condition	 is	 not	 properly	
controlled.		
Due	to	 low	parental	commitment	to	basic	therapy	of	BA	the	cases	of	uncontrolled	clinical	
course	of	the	disease	become	more	and	more	common.	In	Ukraine	there	is	some	fear	of	using	ICS	
and	metered-dose	inhalers	(MDI).	Thus,	an	alternative	administration	of	montelukast	(Milukante)	
orally	 once	 a	 day	 should	 contribute	 to	 a	 better	 control	 of	 the	 disease.	 In	 addition,	 even	 using	
paraclinical	examination	methods	(spirometry	and	peakflowmetry)	BA	can	be	difficult	to	diagnose	
in	young	children.	Therefore,	they	are	recommended	to	use	antileukotriene	drugs	as	monotherapy	
for	at	least	6	weeks	and	if	there	is	an	adequate	response	to	treatment	–	for	3	months.		
The	 objective	 of	 the	 research	 was	 to	 analyze	 the	 effectiveness	 of	 antileukotriene	 drug	
montelukast	as	monotherapy	in	children	with	BA.	
	
Materials	and	methods	
There	were	examined	65	children	with	mild	or	moderate	BA	at	the	age	of	5-7	years	treated	
in	the	allergology	department	of	the	Ivano-Frankivsk	Regional	Children’s	Clinical	Hospital	(RCCH).	
The	prospective	 cohort	 study	 being	 a	 randomized	 open	 one	was	 carried	 out	 considering	
parental	awareness	and	informed	consent,	assessment	of	predictable	risks	and	benefits	according	
to	 Ethical	 Principles	 for	 Medical	 Research	 Involving	 Human	 Subjects	 adopted	 by	 the	 18th	 WMA	
General	Assembly,	Helsinki.		
The	diagnosis	of	BA	was	made,	and	the	degrees	of	severity	and	appropriate	basic	therapy	
were	determined	according	to	the	criteria	approved	by	the	Order	of	MH	of	Ukraine	of	October	08,	
2013	No	868	“Unified	clinical	protocol	of	primary,	secondary	 (specialized)	medical	care	“Bronchial	
Asthma	in	Children”	and	GINA	criteria	(updated	in	2015)	[5,	8,	9].	
All	 patients	 with	 acute	 exacerbation	 of	 moderate	 BA	 being	 treated	 in	 the	 allergology	
department	received	therapy	according	to	“Step-3”:	medium	and	high	doses	of	ICS	and	short-acting	
β2-adrenergic	agonists,	if	necessary.	
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Patients	of	both	groups	received	MDI	salbutamol	and		 fluticasone	 propionate	 (100-125	
mcg	3	times	a	day)	via	the	nebulizer	or	spacer.	Patients	of	Group	 II	received	antileukotriene	drug	
montelukast	 (Milukante	–	1	tablet	at	night:	the	dosage	for	paediatric	patients	 less	than	6	years	of	
age	is	4	mg,	over	6	years	of	age	–	5	mg)	additionally.	Treatment	outcomes	were	evaluated	2	weeks	
after	 the	 beginning	 of	 therapy	 (the	 exacerbation	 period).	 Being	 discharged	 from	 the	 hospital	
children	of	Group	I	received	low-dose	ICS	monotherapy	(50	mcg	of	fluticasone	propionate	twice	a	
day	via	the	spacer),	and	children	of	Group	II	received	montelukast	monotherapy	(1	tablet	at	night;	
the	dosage	for	paediatric	patients	less	than	6	years	of	age	is	4	mg,	over	6	years	of	age	–	5	mg)	[3,	8,	
10,	11].	
The	 concentrations	 of	 total	 immunoglobulin	 E	 (IgE)	 and	 allergen-specific	 IgE	 were	
determined	using	the	Hitachi	Chemical	Diagnostics	chemiluminescent	assay.	
For	daily	monitoring	of	respiratory	function	peakflowmetry	was	performed	using	individual	
peak	 flow	meters	 (Micro	Medical	Ltd,	Great	Britain).	The	peak	expiratory	 flow	 (PEF),	 the	average	
daily	bronchial	patency	 (ADBP)	=	 (PEFmin	+	PEFmax)	 ×100%/2PEFnormal=	 …%	and	 the	daily	bronchial	
patency	variability	 (DBPV)	=	 (PEFmax	–	PEFmin)	×100%/PEFmax	=	…%	were	determined.	The	dynamics	
of	 these	 parameters	 during	 treatment	 was	 evaluated	 calculating	 an	 increase	 in	 ADBP:	 ADBPafter	
treatm	–	ADBPbefore	treatm	=	…%	and	a	decrease	in	DPBV:	DBPVbefore	treatm	–	DBPVafter	treatm	=	…%	[6].	
Mathematical	and	statistical	processing	of	the	results	was	performed	using	a	spreadsheet	
program	Microsoft	Excel	 for	Windows.	Normal	distribution	of	data	and	equality	of	dispersions	 in	
samples	 being	 compared	 were	 proved	 before	 making	 calculations.	 Parametric	 criteria	 were	
calculated	 including	the	arithmetic	mean	of	a	sample	 (M)	and	the	average	error	of	the	arithmetic	
mean	 (m);	 the	 Student’s	 t-test	 was	 used	 to	 compare	 dependent	 samples	 after	 therapy.	 The	
difference	was	considered	significant	(two-sided)	at	p	<0.05.	
	
Results	and	discussion	
When	analyzing	anamnestic	data	 there	were	 recorded	 the	cases	of	underdiagnosis	of	BA	
and	accordingly	inadequate	treatment.	In	60.0%	of	cases	the	first	symptoms	of	asthma	in	children	
were	triggered	by	acute	respiratory	viral	infections	(ARVI).	It	is	important	to	note	that	in	most	young	
children	ARVI	was	often	complicated	by	wheezing	(49.2%)	and	pneumonia	(16.9%)	which	was	rarely	
confirmed	by	chest	X-ray.	Unfortunately,	most	of	these	episodes	were	treated	using	antibacterial	
therapy	despite	normal	values	of	the	complete	blood	count	and	no	infiltrative	changes	in	the	chest	
radiography.	Nearly	half	of	children	were	diagnosed	with	BA	in	the	allergology	department	of	the	
Ivano-Frankivsk	 RCCH	 after	 unsuccessful	 attempts	 of	 treating	 underdiagnosed	 pneumonia	 in	
district	hospitals.		
According	to	parents,	sensitivity	to	indoor	allergens	was	found	to	trigger	disease	in	6.45%	of	
cases	and	sensitivity	to	chemical	mediators	when	making	the	repairs	in	their	apartments	resulted	
in	the	manifestation	of	the	disease	in	7.5%	of	cases.	Sometimes,	asthma	attacks	occurred	secondary	
to	emotional	stress.	The	onset	of	BA	in	healthy	children	was	registered	in	26.2%	of	cases.			
The	analysis	of	the	child’s	feeding	during	the	first	year	of	life	proved	that	breastfeeding	for	
more	 than	 6	 month	 was	 rare.	 The	 severity	 of	 the	 disease	 was	 associated	 with	 lower	 rate	 of	
breastfeeding:	in	mild	BA	23.8%	of	children	were	breastfed	and	in	mild	to	moderate	BA	only	13.0%	
of	children	were	breastfed.	The	obtained	results	suggested	the	dependence	of	BA	on	the	method	of	
feeding	during	the	infant’s	first	year	of	life.	
When	analyzing	allergological	anamnesis	of	patients	other	manifestations	of	atopy	(atopic	
dermatitis,	allergic	rhinitis,	pollinosis)	as	well	as	food	and	drug	hypersensitivity	were	observed	in	
67.7%	of	cases.	 In	addition,	 in	mild	 to	moderate	BA	combined	allergic	pathology	was	observed	 in	
27.7%	of	cases.	
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In	most	cases	the	patient’s	condition	during	remission	was	unsatisfactory.	Symptoms	of	BA	
included	coughing	episodes	in	32.3%	of	cases,	difficulty	in	breathing	and/or	chest	tightness	in	18.5%	
of	cases	indicating	the	absence	of	asthma	control.		
At	 admission	 to	 the	 hospital	 most	 children	 (69.2%)	 were	 diagnosed	 with	 moderate	 BA.	
During	 the	 initial	 examination	 tachypnea	 was	 registered	 in	 all	 children	 and	 tachycardia	 was	
observed	 in	 84.5%	 of	 patients.	 It	 should	 be	 noted	 that	 psychoneurological	 symptoms	 including	
emotional	 lability	 (55.4%),	headache	 (9.2%),	urinary	 incontinence	 (1.5%),	 loss	 of	 appetite	 (43.1%),	
sleep	disruption	(60.0%)	were	often	observed	in	children.	27.7%	of	children	with	BA	complained	of	
abdominal	pain	and	when	palpating	the	abdomen	painfulness	was	observed	in	the	epigastric	area,	
the	 right	 hypochondrium,	 the	 periumbilical	 region	 and	 the	 Kehr’s	 point.	 The	 above-mentioned	
symptoms	may	 indicate	 functional	gastrointestinal	disorders	 (FGID)	due	 to	emotional	 lability	as	
well	as	helminthic	invasion	often	exacerbating	symptoms	of	BA.	
To	diagnose	impaired	bronchial	patency	daily	peakflowmetry	was	added	to	the	complex	of	
examinations	(Table	1).	
	
Table	1	
Parameters	of	peakflowmetry	at	admission,	M±m	
	
Parameters	
Control	group	
(n=20)	
Children	with	bronchial	asthma	
(n=65)	
Average	daily	bronchial	
patency,	%	
93.7±1.0	 58.20±0.72*	
Daily	bronchial	patency	
variability,	%	
4.60±0.41	 29.31±0.71*	
Notes:	*	-	the	probability	of	differences	compared	to	the	control	group,	р<0.001.	
	
At	 admission	 to	 the	 hospital	 in	 all	 patients	 with	 BA	 the	 PEF	 reduced	 by	 1.7-1.9	 times	
compared	to	normal	values	(р<0.001).	
An	increased	total	IgE	level	was	observed	in	most	patients	(86.2%).	
The	 disappearance	 or	 reduction	 in	 main	 symptoms	 of	 the	 disease,	 recovery	 of	 motor	
activities	in	children	or	normalization	of	the	parameters	of	daily	peakflowmetry	served	as	criteria	
for	treatment	efficacy	and	effectiveness.	
The	positive	dynamics	of	clinical	parameters	during	therapy	was	observed	 in	all	children.	
However,	in	patients	receiving	antileukotriene	drug	montelukast	the	improvement	was	registered	
1-3	days	earlier.	On	the	6th	-8th	day	in	Group	I	clinical	stabilization	of	symptoms	of	the	disease	was	
observed	 in	 61.9%	 vs.	 81.0%	 in	 Group	 II	 (р<0.05).	 Subjective	 signs	 included	 improved	 sleep	 and	
appetite,	reduced	manifestations	of		 asthenic	syndrome	and	respiratory	failure,	the	absence	
of	recurrent	asthma	attacks.	Objective	criteria	included	the	improvement	of	auscultatory	findings:	
reduction	in	dry	sibilant	and	buzzing	rales,	or	their	absence,	normalization	of	breathing	and	heart	
rate.	When	assessing	the	values	of	peakflowmetry	the	PEF	was	found	to	be	improved	in	all	children	
(р<0.001),	 however,	 in	 children	 who	 additionally	 received	 montelukast	 better	 parameters	 of	 the	
ADBP	were	observed	77.29±1.17%	vs.	72.87±0.73%	in	Group	 І	(р<0.05).	There	was	a	similar	tendency	
when	 assessing	 the	 increase	 in	 the	 ADBP	 19.9±1.1%	 and	 23.35±1.18%	 in	 Group	 І	 and	 Group	 ІІ,	
respectively	 (Table	 2).	The	DBPV	 reduced	 in	 all	 children	 after	 treatment,	however	 there	was	no	
statistically	significant	difference	between	groups	(р>0.05).		
When	analyzing	the	children’s	general	physical	and	mental	state	3	months	after	undergoing	
basic	 therapy	we	observed	 the	 lack	of	parental	commitment	 to	using	 ICS.	Nearly	half	of	patients	
(18	children)	in	Group	I	stopped	basic	therapy	1	(25.6%)	and	2	months	(20.5%)	after	the	beginning	of	
treatment.	 The	 remaining	 patients	 (21	 children)	 took	 ICS	 irregularly.	 They	 reported	 periodical	
feeling	of	being	unwell,	difficult	breathing	and	cough.	
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Table	2	
Dynamics	of	parameters	of	peakflowmetry	in	children	with	BA	during	treatment,	M±m	
	
Parameters	 ICS	
(Group	І,	n=39)	
ICS+	
montelukast	
(Group	ІІ,	n=26)	
before	
treatment	 after	treatment	
before	
treatment	
after		
treatment	
Average	daily	
bronchial	patency,	
%	
54.02±1.16	 72.87±0.73*	 53.94±0.82	 77.29±1.17*#	
Increase	in	the	
average	daily	
bronchial	patency	
during	treatment,	
%	
	 18.9±1.1	 	 23.35±1.18#	
Daily	bronchial	
patency	
variability,	%	
31.97±1.57	 19.32±0.28*	 29.23±1.01	 20.08±0.33*	
Reduction	in	the	
daily	bronchial	
patency	variability	
during	treatment,	
%	
	 12.65±1.58	 	 9.15±1.13	
Notes:		
1.	*	-	the	probability	of	differences	between	parameters	before	and	after	treatment,	р<0.001;					
2.	#	-	the	probability	of	differences	between	parameters	of	Group	І	та	Group	ІІ,	р<0.05	
	
Patients	of	Group	II	received	basic	therapy	every	day.	Only	three	of	them	(11.5%)	stopped	therapy	1	
month	after	 the	beginning	of	 treatment.	When	assessing	 the	 results	of	peakflowmetry	3months	
after	undergoing	basic	therapy	there	were	detected	some	differences	between	groups	(Table	3).	
	
Table	3	
Dynamics	of	parameters	of	peakflowmetry	in	children	with	BA	3	months	after	undergoing	basic	
therapy,	M±m	
	
Parameters	
ICS	
(Group	І,	n=21)	
Montelukast	
(Group	ІІ,	n=23)	
at	the	beginning	
of	basic	therapy	
3	month	after	
basic	therapy	
at	the	beginning	
of	basic	therapy	
3	month	after	
basic	therapy	
Average	daily	
bronchial	patency,	%	 76.94±0.82	 81.29±1.17*	 77.72±0.78	
89.27±1.11*#	
	
Daily	bronchial	
patency	variability,	
%	
19.23±1.01	 20.08±0.33*	 20.03±1.38	 18.83±0.24	*		
Notes:		
1.	 *	 -	 	 the	 probability	 of	 differences	 between	 parameters	 before	 and	 3	 months	 after	 treatment,	
р<0.001;					
2.	#	-	the	probability	of	differences	between	parameters	of	Group	І	та	Group	ІІ,	р<0.05	
	 	
The	PEF	parameters	remained	moderately	reduced	 in	most	patients,	however,	 in	children	
who	 received	 montelukast	 the	 ADBP	 parameters	 were	 found	 to	 be	 higher	 81.29±1.17%	 vs.	
89.27±1.11%	in	Group	 І	(р<0.05)	and,	accordingly,	the	assessment	of	general	well-being	was	higher,	
too.	 In	 our	 opinion,	 such	 differences	 between	 groups	 are	 explained	 by	 the	 fact	 that	 patients	
Galician	Medical	Journal,	Vol.	23,	No.	1(2016)	
	
journal	homepage:	http://ojs.ifnmu.edu.ua/index.php/gmj/ 
12	
preferred	 taking	 montelukast	 to	 taking	 ICS,	 because	 only	 long-term	 continuous	 basic	 therapy	
according	to	the	GINA	guidelines	has	the	positive	effect.		
	
Conclusions	
1.	The	problem	of	underdiagnosis	of	BA	remains	relevant	to	both	our	region	and	Ukraine	in	
general.		
2.	In	60.0%	of	cases	the	first	symptoms	of	asthma	in	children	were	triggered	by	ARVI.	
3.	The	use	of	antileukotriene	drug	montelukast	(Milukante)	contributes	to	the	reduction	in	
the	 manifestation	 of	 the	 main	 symptoms	 (asthma	 attacks,	 respiratory	 failure,	 cough),	 positive	
dynamics	of	the	parameters	of	peakflowmetry,	normalization	of	the	child’s	overall	wellbeing	over	
a	short	period	of	time.	
4.	There	was	noted	that	patients	preferred	long-term	use	of	antileukotriene	drugs	to	taking	
ICS	(88.5%	vs.	53.8%	of	cases,	respectively).	
	
Prospects	for	further	research	
Prospects	 for	 further	 research	 include	 the	 analysis	 of	 the	 effectiveness	 of	 long-term	
combination	 basic	 therapy	 (ICS	 and	 montelukast)	 in	 children	 with	 moderate	 BA	 compared	 to	
monotherapy	with	ICS.	
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